SEC Form 4 · accession 0001363213-15-000004
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Friedhelm Blobel
Officer — President & CEO · Director
Period of report
May 14, 2015
Accepted (ET)
May 18, 2015 · 7:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 14, 2015 | F | 3,661 | $9.13 | D | 163,991 | D | |
| Common Stock | May 14, 2015 | F | 1,315 | $9.13 | D | 162,676 | D | |
| Common Stock | May 14, 2015 | F | 30,220 | $9.13 | D | 132,456 | D | |
| Common Stock | May 14, 2015 | M | 80,517 | $0.00 | A | 212,973 | D | |
| Common Stock | May 15, 2015 | M | 10,000 | $2.49 | A | 222,973 | D | |
| Common Stock | May 15, 2015 | S$0 | 10,000 | $0.00 | D | 212,973 | D | |
| Common Stock | May 15, 2015 | S$0 | 11,700 | $0.00 | D | 201,273 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3,F4 | $2.49 | May 15, 2015 | M | 10,000 | D | — | Jun 2, 2016 | Common Stock | 10,000 | 709,360 | D |
| Restricted Stock UnitF5,F6 | — | May 14, 2015 | M | 3,500 | D | — | — | Common Stock | 3,500 | 400,517 | D |
| Restricted Stock UnitF5,F7 | — | May 14, 2015 | M | 70,000 | D | — | — | Common Stock | 70,000 | 330,517 | D |
| Restricted Stock UnitF5,F8 | — | May 14, 2015 | M | 7,017 | D | — | — | Common Stock | 7,017 | 323,500 | D |
Explanation of responses
- F1Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units.
- F2The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2014.
- F3Granted under the Issuer's 2005 Equity Incentive Plan.
- F4Provided the reporting person remains employed by or acting as a consultant to the Company, the option will become exercisable in four equal annual installments on 6/02/07, 6/02/08, 6/02/09 and 6/02/10.
- F5Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
- F650% of the restricted stock units will vest on February 20, 2015 and 50% will vest on February 20, 2016, unless the trading window is closed for the Reporting Person on that date, then the vesting date will be deferred until the next date that the trading window is open.
- F7100% of the restricted stock units will vest on March 14, 2015, unless the trading window is closed for the Reporting Person on that date, then the vesting date will be deferred until the next date that the trading window is open.
- F825% of the restricted stock units will vest on May 14, 2012, August 9, 2013, April 5, 2014, and April 5, 2015, unless the trading window is closed for the Reporting Person on that date, then the vesting date will be deferred until the next date that the trading window is open.